Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide MMX maintenance of remission extension study in ulcerative colitis
2008-003913-28Phase 3Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Budesonide MMX 6 mg daily with Placebo daily (2 arms). Primary endpoints: Clinical remission at 1 month, Clinical remission at 3 months and 4 more. Started Apr 2009; status: completed.
02
Drugs
budesonide MMX
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2008-003913-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003913-28.